Opendata, web and dolomites

MCDS-Therapy SIGNED

Repurposing of carbamazepine for treatment of skeletal dysplasia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MCDS-Therapy project word cloud

Explore the words cloud of the MCDS-Therapy project. It provides you a very rough idea of what is the project "MCDS-Therapy" about.

diseases    group    prognosis    450    therapy    bone    chondrodysplasia    innovative    population    mutant    smes    countries    relatively    tools    poor    extremely    lt    gsds    chondrocytes    collaborative    leads    carbamazepine    collagen    minimum    disability    renown    epilepsy    shown    27    least    phenotypes    repurposed    miss    molecules    phase2    hypertrophic    2016    repurposing    authorization    endoplasmic    alleviate    exists    extensive    thereby    extrapolates    approved    fold    marketing    disorder    phase1    centres    caused    er    2022    bipolar    metaphyseal    trial    quality    expression    characterised    lethal    forms    healthcare    reticulum    designation    orphan    cbz    fda    candidate    biomarker    multinational    mcds    synthesis    causing    prevalence    mouse    mutations    model    received    diagnosis    diverse    affordable    strategy    severity    aus    comprising    skeleton    restore    form    225    stress    multicentre    treatment    severe    children    life    pain    world    individually    drug    genetic    personalise    encompasses    economics    september    health    dossier    mild    people    schmid    rare    retained    skeletal    validated    clinical    burden   

Project "MCDS-Therapy" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF NEWCASTLE UPON TYNE 

Organization address
address: KINGS GATE
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU
website: http://www.ncl.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://mcds-therapy.eu/
 Total cost 5˙697˙390 €
 EC max contribution 5˙697˙390 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2017-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2022-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) coordinator 2˙175˙161.00
2    ISTITUTO ORTOPEDICO RIZZOLI IT (BOLOGNA) participant 782˙175.00
3    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 657˙569.00
4    SCIOMICS GMBH DE (HEIDELBERG) participant 604˙030.00
5    FINOVATIS FR (LYON) participant 320˙937.00
6    MURDOCH CHILDRENS RESEARCH INSTITUTE AU (PARKVILLE) participant 318˙625.00
7    FINDACURE FOUNDATION UK (CAMBRIDGE) participant 309˙235.00
8    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 211˙479.00
9    GUYS AND ST THOMAS' NHS FOUNDATIONTRUST UK (London) participant 197˙428.00
10    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 120˙750.00

Map

 Project objective

Genetic skeletal diseases (GSDs) are an extremely diverse and complex group of rare genetic diseases that affect the development the skeleton. There are more than 450 unique and well-characterised phenotypes that range in severity from relatively mild to severe and lethal forms. Although individually rare, as a group of related genetic skeletal diseases, GSDs have an overall prevalence of at least 1 per 4,000 children, which extrapolates to a minimum of 225,000 people in the 27 member states and candidate countries of the EU. This burden in pain and disability leads to poor quality of life and high healthcare costs. Metaphyseal chondrodysplasia, type Schmid (MCDS) results from mutations in collagen X and affects <1/100,000 of the population. Mutant collagen X molecules miss-fold during synthesis and are retained within the endoplasmic reticulum (ER) of hypertrophic chondrocytes, thereby causing ER stress. Our extensive pre-clinical studies have shown that carbamazepine (CBZ) can alleviate ER stress caused by the expression of mutant collagen X and restore bone growth in a validated mouse model of MCDS. CBZ is an FDA approved drug used for the treatment of epilepsy and bipolar disorder and received orphan drug designation by the European Commission for the treatment of MCDS in September 2016. MCDS-Therapy is a 5-year collaborative project comprising world-renown clinical centres and SMEs to advance the repurposing of CBZ for MCDS (up to the Marketing Authorization Application dossier) through a multicentre and multinational (EU & AUS) clinical trial (Phase1, Phase2/3). MCDS-Therapy also encompasses biomarker development and health economics assessment studies to deliver by 2022 an innovative and affordable (CBZ already exists in a generic form) repurposed therapy for MCDS along with the diagnosis/prognosis tools to personalise the treatment strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MCDS-THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MCDS-THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

SBR (2020)

SMART BONE REGENERATION

Read More